KURA Overview
Upcoming Projects (KURA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KURA)
-
A Second Look: Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Tickers: KURA, JNJ, SNDX
Executed On: Jul 17, 2024 at 11:00 AM EDT -
Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Tickers: JNJ, SNDX, KURA
Executed On: Jun 25, 2024 at 09:30 AM EDT -
Digging into the recent data from ASH2022 on Syndax' revumenib (SNDX-5613) & Kura's ziftomenib in treating AML
Tickers: SNDX, KURA
Executed On: Dec 20, 2022 at 05:30 PM EST -
A discussion of ziftomenib (menin inhibitor) and outlook for KOMET-001 trial in r/r AML
Tickers: KURA, SNDX
Executed On: Oct 13, 2022 at 05:00 PM EDT
Expired Projects (KURA)
Upcoming & Overdue Catalysts (KURA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (KURA)
-
Phase 2 additional data of Kura Oncology's(KURA) Tipifarnib in Relapsed or refractory peripheral T-cell lymphoma due at EHA
Ticker: KURA
Occurred on: Jun 14, 2019 -
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
Ticker: KURA
Occurred on: Jun 16, 2016
Strategic Initiatives (KURA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
